Crystalline Salts of Plasma Kallikrein Inhibitor Patent

USPTO granted Patent US12590069B2 to BioCryst Pharmaceuticals, Inc. on March 31, 2026, covering crystalline salt forms of a plasma kallikrein inhibitor (Compound I), related pharmaceutical preparations, and treatment methods. The patent contains 30 claims and provides exclusivity through its filing date of August 28, 2025. CPC classifications include C07D 231/14 and A61K 9/0029.

This is a routine patent grant creating intellectual property rights rather than regulatory obligations. Pharmaceutical companies developing competing plasma kallikrein inhibitors or related compounds should review this patent for potential freedom-to-operate concerns. No compliance deadlines, penalties, or required regulatory filings are associated with this patent grant. Companies seeking similar protection should engage patent counsel for independent filings.